Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

Annals of Neurology

Volumn 39, Issue 3, 1996, Pages 285-294

  Jacobs, Lawrence D ^a,b   Cookfair, Diane L ^b   Rudick, Richard A ^c   Herndon, Robert M ^d   Richert, John R ^e   Salazar, Andres M ^f   Fischer, Jill S ^c   Goodkin, Donald E ^g   Granger, Carl V ^h   Simon, Jack H ⁱ   Alam, John J ^j   Bartoszak, David M ^f   Bourdette, Dennis N ^k   Braiman, Jonathan ^f   Brownscheidle, Carol M ^a   Coats, Michael E ^f   Cohan, Stanley L ^e   Dougherty, David S ^f   Kinkel, Revere P ^c   Mass, Michele K ^d   Munschauer III, Frederick E ^a   Priore, Roger L ^b   Pullicino, Patrick M ^a   Scherokman, Barbara J ^l   Weinstock Guttman, Bianca ^c   Whitham, Ruth H ^k   more..

^a William C Baird Multiple S R C   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g UCSF Multiple Sclerosis Center   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j BIOGEN   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l KAISER PERMANENTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; BETA1A INTERFERON; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BRAIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLACEBOS; RECURRENCE; TREATMENT OUTCOME;

EID: 0008678962     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390304     Document Type: Article

References (34)

1. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal Interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028
2. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal Interferon in multiple sclerosis. Arch Neurol 1982;39:609-615
3. Jacobs L, Salazar AM, Herndon R, et al. Multicenter double-blind study of effect of intrathecally administered natural human fibroblast Interferon on exacerbations of multiple sclerosis. Lancet 1986;2:1411-1414
4. Jacobs L, Salazar AM, Herndon R, et al. Intrathecally administered natural human fibroblast Interferon reduces exacerba-tions of multiple sclerosis: results of a multicenter double-blind study. Arch Neurol 1987;44:589-595
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
6. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant Interferon beta for exacerbating-remitting multiple sclerosis: design and conduct of study; base-line characteristics of patients. Multiple Sclerosis 1995;1:118-135
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 1983;33:1444-1452
9. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacker KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine, vol 2. New York: McGraw-Hill, 1994:2287-2295
10. Efron B. Forcing a sequential design to be balanced. Biometrica 1971;57:403-407
11. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-414
12. Jacobs L, Munschauer FE. Treatment of multiple sclerosis with interferons. In: Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis: trial design, results and future perspectives. London: Springer, 1992:223-250
13. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grade 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42:859-863
14. Lim KO, Pfefferhaum A. Segmentation of MR brain images into cerebrospinal fluid spaces, white and gray matter. J Comput Assist Tomogr 1989;13:588-593
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
16. Mann HB, Whitney DR. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60
17. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621
18. Beck AT, Steer RA. Beck Depression Inventory (BDI) manual. San Antonio: Psychological Corporation, 1987
19. Goodkin DE. Interferon beta-1b. Lancet 1994;344:1057-1060, 1702-1703
20. Katz K, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion develop-ment in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669
21. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
22. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
23. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477-1489
24. Paty D, Willoughby E, Whitaker J. Assessing the outcomes of experimental therapies in multiple sclerosis patients. In: Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis; trial design, results and future perspectives. London: Springer, 1992:47-90
25. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988;38:1793-1798
26. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47
27. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994;36:S108-S112
28. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542-545
29. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207-210
30. Antel JP, Arnason BGW, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979;5:338-342
31. Ransohoff RM, Devajyothi C, Estes ML, et al. Interferon-β specifically inhibits interferon-γ induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991;33:103-112
32. Noronha A, Toscas A, Jensen M.A. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154
33. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high dose recombinant interferon alpha 2a reduces exacerbation rate, MRI signs of disease activity and lymphocyte interferon gamma production in relapsing remitting MS. Neurology 1994;44:406-413
34. Rudick RA, Carpenter CS, Cookfair DL, et al. In-vitro and in-vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta Neurology 1993;43:2080-2087